Literature DB >> 28646286

Rifaximin Re-treatment in Patients with Irritable Bowel Syndrome: Feels Like the First Time?

Francesca Romana Ponziani1, Maurizio Pompili2, Antonio Gasbarrini2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28646286     DOI： 10.1007/s10620-017-4656-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


× No keyword cloud information.
  10 in total

1.  Rifaximin therapy for patients with irritable bowel syndrome without constipation.

Authors:  Mark Pimentel; Anthony Lembo; William D Chey; Salam Zakko; Yehuda Ringel; Jing Yu; Shadreck M Mareya; Audrey L Shaw; Enoch Bortey; William P Forbes
Journal:  N Engl J Med       Date:  2011-01-06       Impact factor: 91.245

Review 2.  Irritable bowel syndrome.

Authors:  Paul Enck; Qasim Aziz; Giovanni Barbara; Adam D Farmer; Shin Fukudo; Emeran A Mayer; Beate Niesler; Eamonn M M Quigley; Mirjana Rajilić-Stojanović; Michael Schemann; Juliane Schwille-Kiuntke; Magnus Simren; Stephan Zipfel; Robin C Spiller
Journal:  Nat Rev Dis Primers       Date:  2016-03-24       Impact factor: 52.329

3.  Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

Authors:  Simone Maccaferri; Beatrice Vitali; Annett Klinder; Sofia Kolida; Maurice Ndagijimana; Luca Laghi; Fiorella Calanni; Patrizia Brigidi; Glenn R Gibson; Adele Costabile
Journal:  J Antimicrob Chemother       Date:  2010-09-18       Impact factor: 5.790

4.  Repeat Treatment With Rifaximin Is Safe and Effective in Patients With Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Anthony Lembo; Mark Pimentel; Satish S Rao; Philip Schoenfeld; Brooks Cash; Leonard B Weinstock; Craig Paterson; Enoch Bortey; William P Forbes
Journal:  Gastroenterology       Date:  2016-08-13       Impact factor: 22.682

Review 5.  Rifaximin for the treatment of irritable bowel syndrome - a drug safety evaluation.

Authors:  Francesca Romana Ponziani; Silvia Pecere; Loris Lopetuso; Franco Scaldaferri; Giovanni Cammarota; Antonio Gasbarrini
Journal:  Expert Opin Drug Saf       Date:  2016-05-23       Impact factor: 4.250

Review 6.  The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin.

Authors:  Francesca Romana Ponziani; Franco Scaldaferri; Valentina Petito; Francesco Paroni Sterbini; Silvia Pecere; Loris R Lopetuso; Alessandra Palladini; Viviana Gerardi; Luca Masucci; Maurizio Pompili; Giovanni Cammarota; Maurizio Sanguinetti; Antonio Gasbarrini
Journal:  Dig Dis       Date:  2016-03-30       Impact factor: 2.404

7.  Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin.

Authors:  Beatrice Vitali; Silvia Turroni; Stefania Serina; Margherita Sosio; Lucia Vannini; Marco Candela; Maria Elisabetta Guerzoni; Patrizia Brigidi
Journal:  Int J Antimicrob Agents       Date:  2008-05-06       Impact factor: 5.283

8.  The Intestinal Microbiota and Irritable Bowel Syndrome.

Authors:  Yehuda Ringel; Tamar Ringel-Kulka
Journal:  J Clin Gastroenterol       Date:  2015 Nov-Dec       Impact factor: 3.062

9.  Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity.

Authors:  M Pimentel; B D Cash; A Lembo; R A Wolf; R J Israel; P Schoenfeld
Journal:  Dig Dis Sci       Date:  2017-06-06       Impact factor: 3.199

10.  Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach.

Authors:  Sara Soldi; Sotirios Vasileiadis; Francesca Uggeri; Mariachiara Campanale; Lorenzo Morelli; Maria Vittoria Fogli; Fiorella Calanni; Maria Grimaldi; Antonio Gasbarrini
Journal:  Clin Exp Gastroenterol       Date:  2015-12-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.